本文選題：舒利迭 + 孟魯司特鈉�。� 參考：《中國工業(yè)醫(yī)學(xué)雜志》2014年01期

【摘要】：將60例塵肺患者隨機分為治療組和對照組,每組30例,治療組給予舒利迭吸入及口服孟魯司特鈉,對照組單純吸入舒利迭,兩組均治療6個月并隨訪6個月。結(jié)果顯示,治療組臨床療效優(yōu)于對照組;治療組治療前、后肺功能各項指標(biāo)差異有統(tǒng)計學(xué)意義(P0.05);治療組治療后嗜酸性粒細(xì)胞(EOS)減少、免疫球蛋白(IgE)降低,與治療前比較差異有統(tǒng)計學(xué)意義(P0.05)。提示舒利迭聯(lián)合孟魯司特鈉可提高塵肺穩(wěn)定期合并哮喘患者的臨床療效。
[Abstract]:60 patients with pneumoconiosis were randomly divided into treatment group (n = 30) and control group (n = 30). The results showed that the clinical curative effect of the treatment group was better than that of the control group, the lung function indexes of the treatment group were significantly different before and after treatment (P 0.05), the eosinophilic granulocyte (EOS) decreased and the immunoglobulin IgE (IgE) decreased after treatment in the treatment group. The difference was statistically significant compared with that before treatment (P 0.05). The results suggest that sultidide combined with montelukast sodium can improve the clinical efficacy of pneumoconiosis combined with asthma.
【作者單位】： 天津市職業(yè)病防治院;
【分類號】：R135.2;R562.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 胡U，

本文編號：1890649